Shionogi and Hitachi launched a generative AI solution to create drug development regulatory documents, aiming to cut creation time by up to 50%.
The collaboration between Shionogi and Hitachi to deploy an AI solution for regulatory document creation marks a significant advancement in pharmaceutical R&D efficiency. By reducing document preparation time by up to 50%, this innovation can accelerate drug approval timelines, lower development costs, and provide a competitive edge in bringing new therapies to market faster.
Shionogi and Hitachi launched an AI solution for drug development regulatory documents.
The system aims to cut document creation time by up to 50%.
This innovation enhances efficiency and accelerates drug development.
This initiative is a collaboration between two Japanese companies, highlighting advancements in AI and pharmaceutical technology within Japan. The solution is aimed at improving drug development processes, which has implications for the Japanese pharmaceutical market and potentially for global regulatory submissions originating from Japan.
The system aims to cut document creation time by up to 50%.
This innovation enhances efficiency and accelerates drug development.
Sign in to save notes on signals.
ログイン